Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Ritter Pharmaceuticals (RTTR) Competitors

Ritter Pharmaceuticals logo

RTTR vs. MBX, AVTE, SBTX, NLTX, CYBN, BIOA, VIRI, WHWK, PYRGF, and OSTX

Should you be buying Ritter Pharmaceuticals stock or one of its competitors? The main competitors of Ritter Pharmaceuticals include MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Silverback Therapeutics (SBTX), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), PyroGenesis Canada (PYRGF), and OS Therapies (OSTX).

Ritter Pharmaceuticals vs. Its Competitors

MBX Biosciences (NYSE:MBX) and Ritter Pharmaceuticals (NASDAQ:RTTR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

0.8% of Ritter Pharmaceuticals shares are held by institutional investors. 52.2% of MBX Biosciences shares are held by company insiders. Comparatively, 15.4% of Ritter Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MBX BiosciencesN/AN/AN/AN/AN/A
Ritter PharmaceuticalsN/AN/A-$10.13MN/AN/A

Company Net Margins Return on Equity Return on Assets
MBX BiosciencesN/A N/A N/A
Ritter Pharmaceuticals N/A N/A -162.05%

In the previous week, MBX Biosciences had 1 more articles in the media than Ritter Pharmaceuticals. MarketBeat recorded 1 mentions for MBX Biosciences and 0 mentions for Ritter Pharmaceuticals. MBX Biosciences' average media sentiment score of 1.16 beat Ritter Pharmaceuticals' score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
MBX Biosciences Positive
Ritter Pharmaceuticals Neutral

MBX Biosciences presently has a consensus price target of $37.57, suggesting a potential upside of 173.25%. Given MBX Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe MBX Biosciences is more favorable than Ritter Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MBX Biosciences
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ritter Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

MBX Biosciences beats Ritter Pharmaceuticals on 7 of the 8 factors compared between the two stocks.

Get Ritter Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RTTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RTTR vs. The Competition

MetricRitter PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$100.15M$763.52M$5.48B$9.51B
Dividend YieldN/A4.84%4.73%4.09%
P/E Ratio-3.391.3428.6723.80
Price / SalesN/A25.20373.9066.58
Price / CashN/A19.5635.4557.96
Price / Book21.706.778.275.55
Net Income-$10.13M-$4.28M$3.24B$259.03M

Ritter Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RTTR
Ritter Pharmaceuticals
N/A$2.17
-1.4%
N/A+835.8%$100.15MN/A-3.397
MBX
MBX Biosciences
2.6288 of 5 stars
$14.96
+2.8%
$37.57
+151.1%
N/A$500.02MN/A0.0036
AVTE
Aerovate Therapeutics
N/A$7.75
-6.4%
N/A-88.5%$224.63MN/A-2.5920High Trading Volume
SBTX
Silverback Therapeutics
N/A$18.35
+2.7%
N/A+68.5%$211.66MN/A-7.5883High Trading Volume
NLTX
Neoleukin Therapeutics
N/A$21.68
-4.6%
N/A-46.3%$203.75MN/A-6.9790
CYBN
Cybin
2.5864 of 5 stars
$7.57
-2.2%
$85.00
+1,022.9%
N/A$178.58MN/A-1.7350
BIOA
BioAge Labs
N/A$4.48
-1.1%
N/AN/A$160.61MN/A0.00N/APositive News
VIRI
Virios Therapeutics
N/A$4.82
+1.0%
$5.00
+3.7%
+2,247.1%$92.82MN/A-17.855Upcoming Earnings
WHWK
Whitehawk Therapeutics
N/A$1.77
-2.2%
N/AN/A$83.39M$25.98M11.0640
PYRGF
PyroGenesis Canada
0.3773 of 5 stars
$0.29
+0.7%
N/A-53.5%$54.23M$9.14M-4.8390News Coverage
Gap Up
High Trading Volume
OSTX
OS Therapies
2.1036 of 5 stars
$1.83
+1.7%
$18.00
+883.6%
N/A$51.42MN/A-2.13N/A

Related Companies and Tools


This page (NASDAQ:RTTR) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners